InvestorsHub Logo
Followers 87
Posts 33678
Boards Moderated 87
Alias Born 03/22/2005

Re: Squeejo post# 27

Tuesday, 10/17/2023 10:06:23 PM

Tuesday, October 17, 2023 10:06:23 PM

Post# of 66
Yes, looking good, and starting to get on people's radar. The CEO has said that he wants the company to be acquired by a larger pharma prior to the Phase 3. The full unblinded Phase 2b results should be coming out within the next several weeks,

The lack of recurrence / reinfection is what will make this the new gold standard for C. Dif. Vancomycin is a broad spectrum antibiotic, and basically zaps the entire intestinal microbiome, leading to C. Dif recurrence. ACXP's drug has a narrow spectrum, and kills the C. Dif while leaving the rest of the microbiome intact. This is going to be the new standard treatment for C. Dif.



---
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACXP News